Family office investments surged in June, reaching 60 deals, up from May's 47 but down 40% year-over-year. Biotech and healthcare led the way, with notable investments in Antheia, a Narcan ingredient maker, attracting family offices like Athos KG and S-Cubed Capital. Other deals included investments in entertainment, showcasing diverse investment strategies among ultra-high-net-worth individuals. The increased activity highlights a growing interest in long-term, impact-driven investments within the biotech sector.

Prepared by Christopher Adams and reviewed by editorial team.